Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.

NCT01961609 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
235
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals